广州市2020年至2022年耐多药肺结核管理策略的实施效果以及影响因素分析

doi:10.3760/cma.j.issn.1007-1245.2024.16.004

国际医药卫生导报 ›› 2024, Vol. 30 ›› Issue (16): 2653-2658.DOI: 10.3760/cma.j.issn.1007-1245.2024.16.004

广州市2020年至2022年耐多药肺结核管理策略的实施效果以及影响因素分析

杨子龙¹ 陈泽莹² 汪敏² 冯治宇² 张宏² 邝浩斌²

¹广州医科大学研究生院，广州　511436；²广州市胸科医院结核内科广州市结核病研究重点实验室呼吸疾病国家重点实验室，广州　510095

收稿日期:2024-01-25 出版日期:2024-08-15 发布日期:2024-09-03
通讯作者: 邝浩斌，Email：kuanghaobin@163.com
基金资助:
广州市科技计划（2023B03J1303、2023A03J0539）；广州市医药卫生科技重大项目（20151A031002）；广州市医学重点学科（2021-2023）结核病学

Analysis of the implementation effect and influencing factors of multi-drug resistant tuberculosis management strategy in Guangzhou from 2020 to 2022

Yang Zilong¹, Chen Zeying², Wang Min², Feng Zhiyu², Zhang Hong², Kuang Haobin²

¹Graduate School of Guangzhou Medical University, Guangzhou 511436, China; ²Department of Tuberculosis, Guangzhou Chest Hospital, Key Laboratory of Tuberculosis Research in Guangzhou, State Key Laboratory of Respiratory Disease, Guangzhou 510095, China

Received:2024-01-25 Online:2024-08-15 Published:2024-09-03
Contact: Kuang Haobin, Email: kuanghaobin@163.com
Supported by:
Guangzhou Science and Technology Plan (2023B03J1303, 2023A03J0539); Major Project of Medical and Health Science and Technology in Guangzhou (20151A031002); Guangzhou Medical Key Discipline (2021-2023, Tuberculosis)

摘要/Abstract

摘要：

¹广州医科大学研究生院，广州　511436；²广州市胸科医院结核内科广州市结核病研究重点实验室呼吸疾病国家重点实验室，广州　510095

关键词:

耐多药肺结核, 治疗转归, 影响因素

Abstract:

¹Graduate School of Guangzhou Medical University, Guangzhou 511436, China; ²Department of Tuberculosis, Guangzhou Chest Hospital, Key Laboratory of Tuberculosis Research in Guangzhou, State Key Laboratory of Respiratory Disease, Guangzhou 510095, China

Key words:

Multi-drug resistant tuberculosis, Treatment outcomes, Risk factors

杨子龙陈泽莹汪敏冯治宇张宏邝浩斌.

广州市2020年至2022年耐多药肺结核管理策略的实施效果以及影响因素分析 [J]. 国际医药卫生导报, 2024, 30(16): 2653-2658.

Yang Zilong, Chen Zeying, Wang Min, Feng Zhiyu, Zhang Hong, Kuang Haobin.

Analysis of the implementation effect and influencing factors of multi-drug resistant tuberculosis management strategy in Guangzhou from 2020 to 2022 [J]. International Medicine and Health Guidance News, 2024, 30(16): 2653-2658.

参考文献

[1] World Health Organization. Global tuberculosis report 2022[R/OL]. Geneva: World Health Organization. https://www.who.int/teams/global-tuberculosis-programme/TB-reports/global-tuberculosis-report-2022.
[2] Dheda K, Mirzayev F, Cirillo DM, et al. Multidrug-resistant tuberculosis[J]. Nat Rev Dis Primers, 2024, 10(1):22. DOI: 10.1038/s41572-024-00504-2.
[3] 律彤,杨云斌,潘颖,等.云南省利福平耐药肺结核患者经济负担现状及影响因素分析[J].中国防痨杂志,2023,45(11):1031-1037.DOI:10.19982/j.issn.1000-6621.20230235.
[4] 顾天成,李恒.两部门印发关于进一步加强耐药结核病防治工作通知[N/OL]. 2023-2-24. https://www.gov.cn/xinwen/2023-02/24/content_5743061.htm.
[5] 邝浩斌,谢育红,冯治宇,等.2014-2019年广州市耐多药肺结核管理策略实施效果分析[J].中国防痨杂志,2021,43(2):113-118.DOI:10.3969/j.issn.1000-6621.2021.02.003.
[6] 广州市卫生健康委员会,广州市财政局.广州市结核病防治经费管理办法(2022年版)[EB].(2022-07-21)[2024-01-24].
[7] World Health Organization. WHO consolidated guidelines on tuberculosis. Module 4: treatment - drug-resistant tuberculosis treatment, 2022 update[R]. Geneva: World Health Organization, 2022.
[8] 中华医学会结核病学分会.中国耐多药和利福平耐药结核病治疗专家共识(2019年版)[J].中华结核和呼吸杂志,2019,42(10):733-749.DOI:10.3760/cma.j.issn.1001- 0939.2019.10.006.
[9] 国家卫生健康委员会办公厅.国家卫生健康委办公厅关于印发中国结核病预防控制工作技术规范(2020年版)的通知[A/0L].(2020-04-02)[2020.06-10]. http://tb.chinacdc.cn/ggl/202004/P020200414515703939844.pdf.
[10] 孙秀香,贺军宁,王鹏雁.共情护理联合多维度健康教育指导对肺结核患者的影响[J].国际医药卫生导报,2024,30(1):160-163.DOI:10.3760/cma.j.issn.1007-1245.2024.01.033.
[11] 伍小英,江坤洪,何刚,等.广州市海珠区重点人群结核病筛查情况分析[J].国际医药卫生导报,2022,28(2):223-228.DOI:10.3760/cma.j.issn.1007-1245.2022.02.019.
[12] Zhang S, Qiu L, Wu D, et al. Predictors for treatment outcomes in patients with multi-drug resistant tuberculosis - China, 2018-2020[J]. China CDC Wkly, 2022, 4(41):907-911. DOI: 10.46234/ccdcw2022.187.
[13] 李硕兰,李明武,李光妹,等.中国耐多药肺结核不良治疗转归影响因素的Meta分析[J].中国防痨杂志,2022,44(12):1303-1313.DOI:10.19982/j.issn.1000-6621.20220212.
[14] 石文卉,初乃惠.耐药肺结核患者氟喹诺酮类药物耐药情况及影响因素[J].中国防痨杂志,2021,43(9):905-909.DOI:10.3969/j.issn.1000-6621.2021.09.009.
[15] 严菁敏,陈莹,于洁,等.基于LASSO-logistic回归的TB/HIV患者抗结核治疗结局影响因素研究[J].现代预防医学,2023,50(22):4039-4045,4051.DOI:10.20043/j.cnki.MPM.202306338.
[16] 薛剑航,曹红,李露,等.308例耐多药肺结核患者的治疗转归及影响因素分析[J].结核与肺部疾病杂志,2024,5(1):44-50.DOI:10.19983/j.issn.2096-8493.20230085.
[17] 李京,高媛,逯嘉,等.四川省肺结核患者2年内复发情况及影响因素分析[J].中国防痨杂志,2023,45(11):1038-1044.DOI:10.19982/j.issn.1000-6621.20230193.
[18] Adane HT, Howe RC, Wassie L, et al. Diabetes mellitus is associated with an increased risk of unsuccessful treatment outcomes among drug-susceptible tuberculosis patients in Ethiopia: a prospective health facility-based study[J]. J Clin Tuberc Other Mycobact Dis, 2023, 31:100368. DOI: 10.1016/j.jctube.2023.100368.
[19] Huangfu P, Ugarte-Gil C, Golub J, et al. The effects of diabetes on tuberculosis treatment outcomes: an updated systematic review and meta-analysis[J]. Int J Tuberc Lung Dis, 2019, 23(7):783-796. DOI: 10.5588/ijtld.18.0433.
[20] Tegegne BS, Mengesha MM, Teferra AA, et al. Association between diabetes mellitus and multi-drug-resistant tuberculosis: evidence from a systematic review and meta-analysis[J]. Syst Rev, 2018, 7(1):161. DOI: 10.1186/s13643-018-0828-0.
[21] Alkabab Y, Warkentin J, Cummins J, et al. Therapeutic drug monitoring and TB treatment outcomes in patients with diabetes mellitus[J]. Int J Tuberc Lung Dis, 2023, 27(2):135-139. DOI: 10.5588/ijtld.22.0448.
[22] Critchley JA, Restrepo BI, Ronacher K, et al. Defining a research agenda to address the converging epidemics of tuberculosis and diabetes: part 1: epidemiology and clinical management[J]. Chest, 2017, 152(1):165-173. DOI: 10.1016/j.chest.2017.04.155.
[23] Nasiri MJ, Zangiabadian M, Arabpour E, et al. Delamanid-containing regimens and multidrug-resistant tuberculosis: a systematic review and meta-analysis[J]. Int J Infect Dis, 2022, 124Suppl 1(Suppl 1):S90-S103. DOI: 10.1016/j.ijid.2022.02.043.
[24] Huerga H, Khan U, Bastard M, et al. Safety and effectiveness outcomes from a 14-country cohort of patients with multi-drug resistant tuberculosis treated concomitantly with bedaquiline, delamanid, and other second-line drugs[J]. Clin Infect Dis, 2022, 75(8):1307-1314. DOI: 10.1093/cid/ciac176.
[25] Hatami H, Sotgiu G, Bostanghadiri N, et al. Bedaquiline-containing regimens and multidrug-resistant tuberculosis: a systematic review and meta-analysis[J]. J Bras Pneumol, 2022, 48(2):e20210384. DOI: 10.36416/1806-3756/e20210384.
[26] Franke MF, Khan P, Hewison C, et al. Culture conversion in patients treated with bedaquiline and/or delamanid. A prospective multicountry study[J]. Am J Respir Crit Care Med, 2021, 203(1):111-119. DOI: 10.1164/rccm.202001- 0135OC.
[27] Seung KJ, Khan P, Franke MF, et al. Culture conversion at 6 months in patients receiving delamanid-containing regimens for the treatment of multidrug-resistant tuberculosis[J]. Clin Infect Dis, 2020, 71(2):415-418. DOI: 10.1093/cid/ciz1084.
[28] Saluzzo F, Adepoju VA, Duarte R, et al. Treatment-shortening regimens for tuberculosis: updates and future priorities[J]. Breathe (Sheff), 2023, 19(3):230028. DOI: 10.1183/20734735.0028-2023.
[29] 张亚萍,牛亚燕,唐佩军.贝达喹啉治疗特殊人群耐药结核病的安全性与有效性研究进展[J].中华结核和呼吸杂志,2023,46(6):619-624.DOI:10.3760/cma.j.cn112147- 20230103-00003.
[30] 张亚萍,唐佩军.德拉马尼治疗特殊人群耐药结核病的安全性与有效性的研究进展[J].中华传染病杂志,2023,41(10):678-682.DOI:10.3760/cma.j.cn311365-20230323-00083.
[31] Kokebu DM, Ahmed S, Moodliar R, et al. Failure or relapse predictors for the STREAM stage 1 short regimen for RR-TB[J]. Int J Tuberc Lung Dis, 2022, 26(8):753-759. DOI: 10.5588/ijtld.22.0073.

广州市2020年至2022年耐多药肺结核管理策略的实施效果以及影响因素分析

Analysis of the implementation effect and influencing factors of multi-drug resistant tuberculosis management strategy in Guangzhou from 2020 to 2022

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

[1]	王磊尤菲张锋吴冠吉刘树文马前锋. 老年心力衰竭患者应用心脏再同步化治疗后无应答的影响因素 [J]. 国际医药卫生导报, 2024, 30(8): 1248-1252.
[2]	吴瑶吕翔. 尘螨过敏哮喘儿童皮下特异性免疫治疗效果的影响因素分析 [J]. 国际医药卫生导报, 2024, 30(8): 1353-1357.
[3]	刘建霞牛路野李亚楠朱小广. 骨质疏松症患者骨折预防知信行调查及胸腰椎骨折的因素分析 [J]. 国际医药卫生导报, 2024, 30(7): 1146-1151.
[4]	吴成慧高红陈慧媛谢辰熙谭玲玲. 中青年2型糖尿病患者智谋现状及影响因素研究 [J]. 国际医药卫生导报, 2024, 30(5): 776-781.
[5]	陈静松刘冉李琦王翔宇. 绝经后女性骨质疏松症预防认知和行为调查及影响因素探讨 [J]. 国际医药卫生导报, 2024, 30(5): 876-880.
[6]	陈泽鑫王育胜林楚纯蔡跃豪袁军. 显微手术夹闭治疗前循环破裂动脉瘤的预后影响因素 [J]. 国际医药卫生导报, 2024, 30(15): 2506-2510.
[7]	李峰苏艺伟王致. 急性百草枯中毒患者预后影响因素分析 [J]. 国际医药卫生导报, 2023, 29(5): 632-637.
[8]	崔金珍董爱芝姜倩倩缪春波李利娟范玉广陈保增常以芳. 心房颤动患者射频消融术后晚期复发的危险因素分析 [J]. 国际医药卫生导报, 2023, 29(5): 637-642.
[9]	黄韵诗杨燕君吴少敏吴嘉婷. 广州市番禺区儿童家长水痘疫苗犹豫现状及其影响因素分析 [J]. 国际医药卫生导报, 2023, 29(24): 3732-3735.
[10]	郑淑倩杨馥曼童红霞. 中老年高磷血症血液透析患者饮食依从性和影响因素分析 [J]. 国际医药卫生导报, 2023, 29(22): 3314-3317.
[11]	季桂安肖斌王慧邹珊伍明称姚金丽冯珂. 脊柱手术术后肺炎的目标性监测 [J]. 国际医药卫生导报, 2023, 29(21): 3056-3060.
[12]	王秋丽罗路路曹玉琴李静. 学龄前1型糖尿病儿童家庭功能的现状及影响因素分析 [J]. 国际医药卫生导报, 2023, 29(2): 212-.
[13]	李钿洪全林加阳林可新李晓红. 中老年患者腰椎融合术后影响加速康复的因素分析 [J]. 国际医药卫生导报, 2023, 29(17): 2507-2512.
[14]	陈劲云莫颖茵刘爱玲高婧郑少敏李佳霓. 基层中医医疗机构患者对中医“治未病”的认知现状及影响因素分析 [J]. 国际医药卫生导报, 2023, 29(16): 2364-2368.
[15]	陶媛程淑琴谢碧霞谢伟成. 血液恶性肿瘤患者并发抑郁的流行病学调查及其影响因素的研究 [J]. 国际医药卫生导报, 2023, 29(15): 2189-2192.